Gestational trophoblastic disease comprises a heterogeneous group of lesions arising from abnormal proliferation of trophoblastic cells. An elevation of human chorionic gonadotropin after evacuation of a molar pregnancy should suggest the hypothesis of a persistent gestational trophoblastic neoplasia. We present a rare case of coexistence of choriocarcinoma and placental-site trophoblastic tumor in the same tumor, whose diagnosis was made based on the correlation of morphological, microscopic and immunocytochemical studies, due to the difficulty in diagnosing these mixed tumors based on conventional histology only.
introDuCtion
Gestational trophoblastic disease (GTD) comprises a heterogeneous group of placental lesions arising from abnormal proliferation of trophoblast. After evacuation of a complete hydatidiform mole (HM), the trophoblastic tissue may persist in 20% of the patients and progress to a gestational trophoblastic neoplasia (GTN). The invasive HM, the placental choriocarcinoma (CC) and the placental-site trophoblastic tumor (PSTT) are grouped under the heading GTNs and have a potential for early vascular invasion and metastasis (13) . CC differs from any type of villous trophoblast and is the most aggressive GTN, occurring in approximately 1/20,000-40,000 pregnancies and in 1/40 complete HM (11) . Histologically, it is a neoplasm with a typical biphasic pattern of cytotrophoblast or intermediate trophoblast, syncytiotrophoblast with cellular pleomorphism, and anaplasia in the absence of chorionic villi (except for the rare cases identified in mature placentas). The invasion of adjacent tissues is many times accompanied by extensive necrosis and hemorrhage, and angioinvasion may be present (1, 2, 15) . This tumor presents with elevated levels of the beta subunit of human chorionic gonadotropin (β-hCG) and is highly chemosensitive (1, 12) .
PSTT is the rarest GTN, and corresponds to less than 0.2% of all GTD cases. It may also develop after any type of pregnancy, mainly confined to the uterus, and in 70% of the cases displays benign behavior. However, there is no specific clinical or pathologic characteristic to predict its eventual malignancy. At histology, it presents as a monomorphic proliferation of extravillous or intermediate trophoblast cells (it belongs to the subgroup of intermediate trophoblastic tumors [ITTs] ) with occasional giant multinucleated cells that infiltrate and split myometrium or endomyometrium (7) . Chorionic villi are seldom found, and the biphasic pattern typical of CC is absent. Normally, a variable amount of inflammation and necrosis is identified, but the marked necrosis and the hemorrhage typical of CC are not present. This tumor secretes small amounts of β-hCG; as a result, a large-volume tumor may be present before the increase of serum β-hCG levels (3) . Histological characteristics, like deep myometrial invasion, high mitotic index (more than five mitoses per 10 high-power fields), tumor cells with clear cytoplasm and necrosis, are more common in more aggressive tumors (5) .
Immunohistochemistry shows a high proportion of cells positive for human placental lactogen (hPL) reflecting the origin of the lesion -the intermediate trophoblast -, and focal positivity for placental alkaline phosphatase (PLAP) and cytokeratins are markers of PSTT, with a specificity of around 60% (14) . Positive immunohistochemical staining for inhibin α confirms the diagnosis of PSTT.
The role of adjuvant chemotherapy is controversial in PSTT, namely in stages I (Table) , and there is no benefit in the 10-year survival rate. Therefore, unless risk factors for the disease recurrence are present, surgery is the most acceptable strategy (10) .
The coexistence of several GTNs in the same lesion is rare, and specific immunohistochemical studies are necessary to identify them. Genetic testing may complement diagnosis, since most PSTTs are diploid. In the GTN classification, the exclusion of mixed components by immunohistochemical studies that permit their identification is important, because their presence carries distinct clinical and therapeutical implications (6) . As chemotherapy has a limited role in the treatment of ITTs, it is especially problematic when they are mixed with CC.
In summary, staging and pre-therapeutic assessment of GTNs, especially of ITTs, are important to stratify patients and select the adequate treatment to each clinical case, normally based on the anatomical extension of the disease and the histological and immunohistochemical studies
CASE rEPort
A 30-year-old female primipara with fertility desire presents at the urgency service with a history of 10-week amenorrhea and genital hemorrhage. At admission she was afebrile, normotense and eupneic. She had slight uterine bleeding, uterus increased in size and painful to palpation, and adnexal areas with no alterations. From the laboratory point of view, only persistently high β-hCG levels ( Figure 1 ) and subclinical hyperthyroidism stood out: hemoglobin -11.5 g/dl; β-hCG -2,531 mUI/ml; thyroid-stimulating hormone (TSH) -0.01 mUI/ml (normal: 0.35-5.5); free thyroxine (T4) -2.83 ng/dl (normal: 0.8-1.76). The gynecologic ultrasound scan showed a heterogeneous mass filling the uterine cavity; trophoblastic disease was suspected, compatible with the hypothesis of complete HM. Chest radiograph did not reveal alterations. The patient underwent cervical dilation and aspiration of the uterine content. The histological diagnosis confirmed the pre-surgical hypothesis. During clinical follow-up, the patient kept the genital hemorrhage, and a considerable increase on β-hCG level was identified, reaching 38,288 mUI/ml in the fifth day after surgery (Figure 1 ). The pelvic ultrasound scan revealed ovaries increased in size due to the presence of anechogenic images suggestive of theca luthein cysts (113 × 87 × 60 mm); the uterus displayed a hypervascularized central area of heterogeneous structure, infiltrating the anterior and posterior myometrial wall (Figure 2) . A computed tomography (CT) scan was carried out in thoracic, abdominal and pelvic regions, evidencing globular uterus, with heterogeneous appearance, and central hypodense areas indicating residual lesion. Due to the hypothesis of invasive mole/CC, and at the patient's request, after multidisciplinary discussion, total hysterectomy was performed, with conservation of anexa (Figure 2 ).
Post-molar trophoblastic neoplasia: A) HE, villi with marked edema with formation of cistern with acellular center, without blood vessels, absence of normal villi; B) marked proliferation of trophoblast, positivity for β-hCG (+++); C) PLAP (+). Endomyometrial invasive lesion: D-H) HE, CC component with pleomorphism and acellular atypia, mitoses (arrow), polarization to vascular structures (arrow head), hemorrhage and necrosis. Immunohistochemical profile: I) strongly marked β-hCG (+++); J) strongly expressed AE1/ AE3 (+++), straight muscle fibers with weak expression for epithelial markers and in the PSTT component; L) weakly marked inhibin (+); M) moderately marked PLAP (++
The histological examination showed cell component with extravillous trophoblast proliferation (immunohistochemical study positive for PLAP and inhibin [ Figure 3] ). Hemorrhage, coagulative necrosis, fibrinoid material at the area of ovum implantation, and inflammatory component favored the diagnosis of PSTT. Immunohistochemistry also revealed the proliferation component of villous trophoblast (positivity for β-hCG), thus confirming the coexistence of gestational CC (Figure 3 ).
At six months of clinical follow-up, β-hCG levels had returned to normal (43 days after intervention) and clinical picture, imaging and laboratory results were stable. Nowadays, three years after diagnosis, the patient is clinically well, in complete remission of the disease, without adjuvant therapy.
DiSCuSSion
An invasive heterogeneous endomyometrial neoplasm was identified in this case, with hemorrhage and necrosis, which microscopically presents cellular pleomorphism and atypia, with low mitotic index. There is cell polarization to vascular structures, and the presence of hemorrhage and necrosis. Immunohistochemical studies show an expression common to PSTT and CC in a patient with a previous diagnosis of complete HM. The absence of a different "collision" pattern in both cellular components and their intimate coexistence in the same lesion make diagnosis many times difficult, requiring an immunohistochemical study to identify the different components, and thus, to reach a more precise classification regarding histogenesis of the several constituents (Figure 3 (4, 6) .
Although rare forms of GTN, they can make histological classification difficult and their recognition is important because they need distinct therapies. Distinguishing ITT from CC is essential, given the limited value of chemotherapy in ITT, contrary to what happens with CC (9) . Immunohistochemistry, by means of markers as human leukocyte antigen G (HLA-G), cluster of differentiation 10 (CD10), and hCG, is a good resource and may be useful in the differential diagnosis and identification of ITTs.
The factors of prognosis worsening present in this patient were, in histological terms, the deep myometrial invasion, and, in clinical terms, the high β-hCG levels, besides the coexistence of two GTNs and the fact that PSTT is not chemosensitive.
Thus, it is a rare combination of invasive endomyometrial lesion with morphological and immunohistochemical characteristics common to CC and PSTT. Molecular studies were not undertaken, and chromosomal anomalies are highly complex in CC with amplification of 7p and deletion of 8p, without apparent relationship with the type of previous pregnancies; the diploid profile XX is present in most CCs. Malignant PSTTs show rare alterations in genome hybridization and in situ hybridization studies (8) .
A mixed trophoblastic tumor with CC and PSTT component is an extremely rare presentation, but highly curable and with good prognosis, if detected early (6) . As the clinical spectrum and presentation of GTNs vary a lot, early diagnosis and the timely institution of therapy are fundamental to a favorable clinical outcome (12) .
